ICER warns of lack of value with high-priced ALS drugs
Never afraid to point out perceived overpricing of medicines on the US market, the Institute for Clinical and Economic Review (ICER) has focused on treatments for amyotrophic lateral sclerosis (ALS) in its latest assessment.
The ICER has published its revised Evidence Report assessing the comparative clinical effectiveness and value of Amylyx Pharmaceuticals’ (Nasdaq: ALX) AMX0035 and Mitsubishi Tanabe Pharma’s (TYO: 4508) oral edaravone.
David Rind, ICER’s chief medical officer, said: “There is tremendous need for new therapies in ALS.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze